Portfoliotracker

Vogenx, Inc.

VOGX · NASDAQCM · Healthcare Biotechnology

14,38 $
▼ −2,29 (−13,74 %)
Pre-market delayed by 15 min
Price as of 16. 11. 22:00, fetched 17. 11. 13:54
Next earnings–
Ex-dividend–
Analysts–
50 / 200 day average– / –

Price

Portfoliotracker score– Market cap150 mil. $ P/E– Forward P/E– P/S– P/B1,8 EV/EBITDA– Dividend yield– FCF yield-0,58 % EPS-0,89 $ Net margin0,0 % Return on equity– Beta– Debt / equity–
52-week range 12,61 to 38,41
3-month average volume0,1 M

Finance

Where the revenue goes

Loading the income statement flow…

Fundamentals

Loading key figures…

Insiders, analysts and people

All trades and changes

Loading insiders, analysts and opinions…

Co se právě děje

AI souhrn
Objednat AI souhrn, co se u firmy právě děje Vytvoří se jednou na pozadí a pak ho uvidí všichni. Ve verzi Free 3 objednávky měsíčně.

About the company

Vogenx, Inc. operates as a clinical-stage drug development company that develops therapeutics for metabolic including post-bariatric hypoglycemia, or PBH, and gastroparesis. Its products include drugs, such as Mizagliflozin and VGX-2857. It also offers VGX-001, a human monoclonal antibody for the treatment of type 1 diabetes (T1D). It caters to healthcare providers, physicians and third-party payors in the United States. The company was incorporated in 2021 and is based in Raleigh, North Carolina.

Website
vogenx.com
Employees
4
Country
United States
Fiscal year end
31. 12.
Data since
12. 8. 2026

Explore further

Similar companies LTGOCOAGBLSMBRVEODTX

Intraday chart

Your own portfolio, properties and finances in one place.

The account is free with no time limit. Only you see your data; nobody adds it up with others.

This is saved to your account. You can keep browsing, calculating and comparing without signing in.

Welcome back

Sign in and pick up where you left off.

or continue with

No account yet? Create a free account